JP Morgan Chase’s Syndax Pharmaceuticals SNDX Stock Holding History

JP Morgan Chase’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-29,900	Closed	-$395K	–	7694
2024 Q4	$395K	Sell	29,900 -4,300	-13%	-$73.6K	﹤0.01%	5158
2024 Q3	$658K	Hold	34,200	–	–	﹤0.01%	4739
2024 Q2	$702K	Hold	34,200	–	–	﹤0.01%	4494
2024 Q1	$814K	Buy	+34,200	New	+$763K	﹤0.01%	4488
2023 Q4	–	Sell	-125,000	Closed	-$1.81M	–	7848
2023 Q3	$1.81M	Buy	+125,000	New	+$2.36M	﹤0.01%	3610

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

JP Morgan Chase's SNDX Position: Q1 2026 in Review

JP Morgan Chase reduced its Syndax Pharmaceuticals (SNDX) stake by 32% in Q1 2026, selling an estimated $2.61M and leaving 258,519 shares worth $5.81M. The position accounts for ﹤0.01% of the portfolio, ranked #3181.

JP Morgan Chase first reported a position in SNDX in Q2 2016 and has held it in 39 quarters since. The position peaked at $16.9M in Q4 2023. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

JP Morgan Chase held 258,519 shares of Syndax Pharmaceuticals worth $5.81M as of Q1 2026.
JP Morgan Chase sold 119,985 Syndax Pharmaceuticals shares in Q1 2026, an estimated $2.61M.
Syndax Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3181 holding.
JP Morgan Chase first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 39 quarters since.
JP Morgan Chase's Syndax Pharmaceuticals position peaked at $16.9M in Q4 2023.
246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.